Skip to content

Pasadena Star News

64°F
Friday, May 1st 2026

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Certara, Inc. - Common Stock (NQ:CERT)

6.810 +0.260 (+3.97%)
Streaming Delayed Price Updated: 9:58 AM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Certara, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
ArrowMark Slashes Alight Position Amid Growing Questions About Its Recurring-Revenue Strategy ↗
ArrowMark’s sharp reduction in its Alight stake comes at a moment when the market is questioning whether the company can turn its consulting-heavy work into steadier recurring revenue, and that tension... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The Next Wave Of AI Winners? Investors Shift Focus Beyond Nvidia ↗
Goldman Sachs says investors are shifting toward companies quietly using AI to cut costs and drive productivity-led growth. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Certara Reports Third Quarter 2025 Financial Results
Updates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Certara Automates Scientific Workflows with Phoenix® Cloud
New cloud capabilities cut time to create Tables, Figures, and Listings by 50% 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara Expands Biosimulation Market with AI-Driven QSP Platform
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies 
From Certara
Via GlobeNewswire
News headline image
Certara Scientists are Among the Topmost Cited Biopharma Researchers
Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025
From Certara
Via GlobeNewswire
News headline image
Beyond The Numbers: 4 Analysts Discuss Certara Stock ↗
 
Via Benzinga
News headline image
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Certara Launches Pinnacle 21® Enterprise Plus to Deliver Regulatory Submissions Faster
Solution delivers a 50% reduction in time spent drafting mapping specifications, according to internal measurements 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
Certara (CERT) Q2 Revenue Jumps 12% ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Certara Reports Second Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling
From Certara
Via GlobeNewswire
News headline image
Certara Appoints Dr. Chris Bouton as Chief Technology Officer to Advance AI in-silico Drug Discovery and Development Platform
Strengthening technology innovation and leadership of the Certara AI/ML-enabled biosimulation platform used to speed time to market in drug discovery and development 
From Certara
Via GlobeNewswire
News headline image
Certara to Report Second Quarter 2025 Financial Results on August 6th, 2025
From Certara
Via GlobeNewswire
News headline image
Certara Announces Expansion of Clinical Technology Collaboration with Merck
Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality 
From Certara
Via GlobeNewswire
News headline image
What Analysts Are Saying About Certara Stock ↗
 
Via Benzinga
News headline image
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Certara Reports First Quarter 2025 Financial Results
Reiterates Full Year 2025 Financial Guidance 
From Certara
Via GlobeNewswire
News headline image
Certara to Participate in Upcoming Investor Conferences
From Certara
Via GlobeNewswire
News headline image
3 Momentum Stocks That Could Soar Post-Market Volatility
Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum? 
Via MarketBeat
Topics Artificial Intelligence World Trade
News headline image
Hertz Global And Webull Stocks Are Among Top Mid-Cap Gainers Last Week (Apr 14-Apr 18): Are The Others In Your Portfolio? ↗
Top mid-cap performers last week: Webull Corp, Hertz Global, Metsera Inc, Vista Energy, Certara Inc, Sibanye-Stillwater, Banco Macro, Grupo Financiero Galicia, Banco BBVA Argentina, Recursion... 
Via Benzinga
News headline image
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News ↗
Via Stocktwits
Topics Animal Testing Artificial Intelligence Stocks
News headline image
Top 3 Health Care Stocks You May Want To Dump This Quarter ↗
 
Via Benzinga
News headline image
Certara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report ↗
Certara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.